progression-free survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xue-Feng Kan, Bin Liang, Xiao-Lin Zhang, Lei Yu, Yao-Chang Luo, Shi Zhou, Rui-Bao Liu, Guo-Hui Xu, Hai-Liang Li, Zheng-Yin Liao, Hua Xiang, Wei Lu, Lin-Feng Xu, Yi-Long Ma, Xiang-Wen Xia, Kun Qian, Xiang-Jun Dong, Fu Xiong, Song-Lin Song, Chang Zhao, Ming Huang, Chuan-Sheng Zheng
BMC Med 23(1) 313
BACKGROUND: This study aimed to assess the efficacy and safety of transarterial chemoembolization (TACE) in combination with apatinib (TACE-apatinib) for patients with unresectable hepatocellular carcinoma (HCC). METHODS: This study was a multicenter, randomized, open-label, prospective, phase III trial. Patients with unresectable HCC were randomly assigned in a 1:1 ratio to receive either TACE-apatinib or TACE-alone treatment. Patients in the TACE-apatinib group began with a dosage of 500 mg/day of oral apatinib administered 4 days after the first TACE. The primary endpoint of this study was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to untreatable (unTACEable) progression (TTUP), and safety assessment. RESULTS: From November 1, 2018 to November 18, 2021, a total of 196 patients were randomly assigned to either the TACE-apatinib (n = 86) or TACE-alone (n = 92) group. The median PFS in the TACE-apatinib group was significantly longer than that of in the TACE-alone group (6.1 months vs. 3.4 months, p < 0.0001). The median OS was significantly prolonged in the TACE-apatinib group compared to the TACE-alone group (28.9 months vs. 24.0 months, p = 0.0005). The median TTUP in the TACE-apatinib group was 26.8 months, which was significantly longer than that of 20.1 months in the TACE-alone group (p = 0.0003). A significantly higher ORR and DCR were observed in the TACE-apatinib group compared to the TACE-alone group (ORR: 58.1% vs. 31.5%, p < 0.001; DCR: 87.2% vs. 69.6%, p = 0.004). Most of the treatment-related adverse events were grades 1-2, and no treatment-related deaths were observed. CONCLUSIONS: Apatinib significantly improved the treatment effects of TACE for patients with unresectable HCC. TACE-apatinib could serve as a promising treatment option for this patient population, offering notable survival benefits while maintaining an acceptable safety profile. TRIAL REGISTRATION: Chinese Clinical Trial Register, No. ChiCTR1800018621.
1 个 Figure · 1 个 KM 面板
Kaplan–Meier curve ( A ) and forest plot ( B ) of progression-free survival for patients in the TACE-apatinib group and TACE-alone group. TACE, transarterial chemoembolization; TACE-apatinib, TACE combined with apatinib
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。